Key upcoming dates in Jordan:
30 June 2023 – Deadline for the application of 2D data matrix codes and serialization on secondary packaging of pharmaceutical products.
Introduction
The JFDA was created in 2003 to ensure the safety and efficacy of drugs and the quality and safety of food. After postponing the implementation of 1D linear and 2D data matrix codes several times in recent years, the JFDA has now established new regulations for the application of 2D data matrix codes and serialization on secondary packaging of pharmaceutical products.
Implementation timeline:
- June 30, 2023: Deadline for 2D data matrix codes and serialization on secondary packaging
- By this date, pharmaceutical companies in Jordan must apply 2D data matrix codes and serialization on secondary packaging of their products to comply with the JFDA's regulations.
Product Identification
To facilitate the visual correct reading control together with a two-dimensional bar code is applied Human-Readable Information (HRI), which includes the following elements:
- Global Trade Item Number (GTIN)
- Batch or Lot Number
- Expiry Date
- Randomized Serial Number
Compliance
It is important for pharmaceutical companies to work closely with their supply chain partners and technology vendors to ensure that their serialization solutions comply with JFDA regulations and meet the required deadlines. Non-compliance with serialization requirements can result in penalties and delays in product registration and market access in Jordan.
How can CosmoTrace help?
We provide serialization consulting, implementation & integration services to help our clients with managing the end-to-end serialization projects and preparing them for the existing and upcoming regulations across the globe.
We are well versed with the compliance regulations for various markets and can help you with implementing the Jordan pharmaceutical serialization requirements.
Our team of experts strategize and plan end-to-end solutions using a combination of years of knowledge in product serialization, pharmaceutical supply chains, life sciences and brand integrity.
Disclaimer
This information is being provided ‘As Is’ with no claims of suitability for a particular purpose. It represents just one possible interpretation of information available in the public domain or through membership organizations, and that interpretation is subject to change. This information does not constitute legal advice. Users must refer to the source material for the complete requirements and form their own interpretation before making business decisions. Please use the references below to follow the updates at the source.
References
